Clinical Trial Update: Secukinumab in Active Non-segmental Vitiligo [Phase 4]

View source ↗

Summary

Phase 4 clinical trial investigating secukinumab in active non-segmental vitiligo has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vitiligo

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: University Hospital, Ghent | Conditions: Vitiligo, Secukinumab | Phase 4 | Status: COMPLETED